SCHEMBL6929698

SCHEMBL6929698

CC(C)(C)c1cc(N)c(O)c(-n2nc3ccccc3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
LMNA P02545 2/20 0.44
POLB P06746 4/20 0.43
ALDH1A1 P00352 6/20 0.40
MEN1 O00255 6/20 0.40
MAPT P10636 6/20 0.40
KMT2A Q03164 6/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
RECQL P46063 1/20 0.40
KDM4E B2RXH2 7/20 0.36
HPGD P15428 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALOX15 P16050 2/20 0.36
CASP1 P29466 2/20 0.36
HSD17B10 Q99714 2/20 0.36
USP2 O75604 2/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL105823 0.85 NPC1 (0.43) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL108807 0.85 NPC1 (0.54) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL29813370 0.85 NPC1 (0.54) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL30893054 0.85 NPC1 (0.50) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL9567799 0.85 NPC1 (0.50) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL7574172 0.85 NPC1 (0.50) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL29708 0.84 NPC1 (0.49) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL29350736 0.84 NPC1 (0.49) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL9408718 0.82 NPC1 (0.48) NPC1RAB9ALMNAPOLBALDH1A1
SCHEMBL10596458 0.82 NPC1 (0.67) NPC1RAB9ALMNAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944624-B1 INSOLUBLE S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS OREAL (FR) 2003-11-05 EP disclosed
CN-1123572-C Insoluble s-triazine derivatives, process for their preparation, compositions containing them and their use OREAL (FR) 2003-10-08 CN disclosed
US-6517742-B1 2-(butyl 4'-ylaminobenzoate)-4,6-bis((1,3,3,3-tetramethyl-1 -((trimethylsilyl)oxy)disiloxanyl)propyl-3-ylamino)-s-triazine; s-triazine derivatives substituted by at least one silicone group; from cyanuric chloride L'OREAL (FR) 2003-02-11 US disclosed
US-6361764-B2 ULTRAVIOLET LIGHT SCREENING AGENTS; COSMETICS SOCIETE L'OREAL S.A. (FR) 2002-03-26 US disclosed
US-20020010179-A1 Novel insoluble S-triazine derivatives, process for their preparation, compositions containing them and uses thereof RICHARD HERVE (FR) 2002-01-24 US disclosed
CN-1240446-A Insoluble s-triazine derivatives and their use as UV absorbers OREAL (FR) 2000-01-05 CN disclosed
EP-0944624-A1 INSOLUBLE S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS L'OREAL (FR) 1999-09-29 EP disclosed
EP-0841341-B1 Sunscreen agents, and cosmetic compositions containing them OREAL (FR) 1999-04-07 EP disclosed
WO-1998025922-A1 INSOLUBLE S-TRIAZINE DERIVATIVES AND THEIR USE AS UV FILTERS L'OREAL (FR) 1998-06-18 WO disclosed
EP-0841341-A1 Sunscreen agents, and cosmetic compositions containing them L'OREAL (FR) 1998-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010179-A1 Novel insoluble S-triazine derivatives, process for their preparation, compositions containing them and uses thereof TST, TYR, TPST2 NPC1 3874/4885RAB9A 4784/4885LMNA 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.